Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Overview
Pacira BioSciences Inc (NASDAQ: PCRX) is a specialty pharmaceutical company committed to revolutionizing pain management by offering innovative non-opioid therapies and regenerative health solutions. With a core focus on providing safe and effective alternatives for pain control, the company leverages its proprietary drug delivery platforms to address acute pain in surgical and chronic conditions. Its approach combines advanced pharmaceutical formulations with novel medical devices, ensuring that clinicians have access to effective treatment options that reduce reliance on opioids.
Core Technologies and Products
At the heart of Pacira's innovation is its unique product delivery technology, which encapsulates active compounds without altering their molecular structures. This platform enables controlled, extended release of medications, ensuring long-lasting efficacy. The company has successfully commercialized several non-opioid treatments:
- EXPAREL: A long-acting local anesthetic designed to provide postsurgical pain control through sustained drug release, thereby reducing the need for opioids.
- ZILRETTA: An extended-release intra-articular injection indicated for the management of osteoarthritis knee pain, offering patients prolonged relief.
- iovera®: A handheld, drug-free device that applies controlled doses of cold therapy to targeted nerves, providing immediate and lasting pain relief.
In addition to these commercial products, Pacira is advancing its pipeline with a novel gene therapy candidate, PCRX-201. This locally administered therapy aims to treat osteoarthritis by regulating inflammatory pathways, thus addressing the root causes of pain and disability.
Market Position and Business Model
Pacira BioSciences operates at the intersection of innovative drug delivery and non-opioid pain management solutions. Its business model emphasizes:
- Commercialization of Proven Therapies: The company has established a presence in markets requiring effective postsurgical and chronic pain management solutions, evidenced by the wide adoption of its therapies in diverse clinical settings.
- Advanced R&D and Pipeline Development: By investing in robust research and development programs, along with strategic partnerships, Pacira continues to expand its portfolio and maintain competitive differentiation in the specialty pharmaceutical sector.
- Regulatory and Reimbursement Strategies: With products that have secured critical reimbursement designations, Pacira enhances market access for its non-opioid therapies across different healthcare settings. This strategic emphasis supports clinician adoption and broader patient access.
Clinical and Commercial Significance
The company's focus on non-opioid pain management comes at a time when reducing opioid dependency is an urgent priority in healthcare. By developing treatments that not only manage pain effectively but also minimize opioid consumption, Pacira is addressing a key public health challenge. Its clinically validated products have been incorporated into pain management protocols in hospitals and outpatient settings alike, offering enduring benefits for patients and healthcare providers.
Innovative Edge and Future Pipeline
Pacira’s utilization of advanced drug delivery systems, such as multivesicular liposomes and precise cryoneurolysis, underscores its commitment to innovation. These technologies not only improve therapeutic outcomes but also facilitate streamlined billing and regulatory approval processes through established coding systems. With an evolving pipeline that includes gene therapy approaches, the company is poised to expand its reach into additional therapeutic areas, addressing unmet needs in the treatment of chronic and musculoskeletal pain.
Competitive Landscape and Differentiators
In a competitive market, Pacira differentiates itself through its deep expertise in non-opioid pain management and its commitment to technological advancements. The integration of robust clinical data, strategic reimbursement initiatives, and a focus on delivering sustained therapeutic benefits positions the company as a trusted innovator among healthcare practitioners. Unlike traditional pain management solutions that rely heavily on opioids, Pacira’s products are designed to provide effective relief with reduced risk of dependency, offering a clinically superior alternative in the evolving landscape of pain management.
Conclusion
With a comprehensive portfolio that spans commercial-stage products and a promising pipeline, Pacira BioSciences Inc stands as a key player in the specialty pharmaceutical industry. Its ongoing commitment to developing non-opioid pain therapies, underpinned by advanced drug delivery technologies and rigorous clinical validation, ensures that it remains an authoritative source of innovation and expertise in pain management and regenerative health.
Pacira BioSciences (PCRX) and IPG have announced a partnership aimed at reducing postsurgical opioid prescriptions and lowering surgical costs across IPG's health plan network. The collaboration will see IPG reimbursing for EXPAREL®, a non-opioid pain management solution, to enhance surgical care quality and affordability. Both companies will create educational resources to optimize pain management practices, with Pacira emphasizing the benefits of non-opioid approaches for improved patient outcomes and satisfaction.
PARSIPPANY, N.J., Sept. 11, 2020 - Pacira BioSciences, Inc. (NASDAQ: PCRX) will present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 3:30 PM ET. Interested parties can listen to the live audio through the company’s website. A replay will be available for two weeks post-event. Pacira specializes in non-opioid pain management solutions, with its flagship product, EXPAREL®, launched in April 2012. The firm advocates for reduced opioid reliance in healthcare.
Pacira BioSciences (PCRX) reported preliminary August 2020 net product sales of EXPAREL at $36.1 million, reflecting average daily sales at 111% of 2019 levels. The rise in sales is attributed to the growing adoption of EXPAREL among surgical centers and anesthesiologists, driven by a shift towards outpatient procedures as restrictions on elective surgeries ease amid COVID-19. The company aims to provide transparency by reporting monthly sales until full visibility on pandemic impacts is achieved. Financial data is preliminary and unaudited.
Pacira BioSciences (Nasdaq: PCRX) reported Q2 2020 revenues of $75.5 million, down 26% from $102.6 million in Q2 2019, largely due to the impacts of COVID-19. EXPAREL net sales were $73.0 million, also down by 26%. The company’s GAAP net loss reached $7.3 million ($0.17 per share), contrasting with a net income of $2.7 million in the same period last year. Total operating expenses decreased to $82.7 million. Pacira has seen a recovery in EXPAREL sales since April and aims to expand its non-opioid pain management solutions. The FDA accepted an sNDA for EXPAREL for pediatric use, with an expected decision by March 2021.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020, at 9:10 AM ET. Interested parties can access the live audio via the company’s website. A webcast replay will be available for two weeks post-event. Pacira specializes in non-opioid pain management solutions, including EXPAREL® and the iovera⁰ system.
Pacira BioSciences announced the publication of its Phase 4 study results for EXPAREL in Anesthesia and Analgesia. The study showed a 52% reduction in total opioid consumption at 72 hours post-C-section when combined with bupivacaine, and a statistically significant increase in opioid-spared patients (54% vs 25%). The study spanned 13 sites and involved 136 patients. Safety was comparable between groups, with 64% of the EXPAREL group experiencing treatment-emergent adverse events. This data could enhance postoperative pain management strategies, especially given that C-sections pose significant opioid use concerns.
Pacira BioSciences announced that the FDA has accepted its supplemental new drug application (sNDA) for EXPAREL, aiming to expand its label to include postsurgical analgesia for children aged six and over. Based on positive Phase 3 study results showing favorable pharmacokinetics and safety profiles, the FDA's action date is set for March 22, 2021. If approved, EXPAREL will become the first long-acting local anesthetic sanctioned for pediatric use, addressing the urgent need for non-opioid pain management alternatives in children, who typically rely on opioids for post-surgery pain relief.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will report its second quarter financial results on August 6, 2020, before market opening. Following the announcement, a live conference call will take place at 8:30 a.m. ET. Participants can join via a dedicated dial-in number or through a webcast available on the company’s investor page. A replay of the call will be accessible for one week post-event. Pacira specializes in non-opioid pain management and regenerative health solutions, prominently featuring its long-acting analgesic, EXPAREL®, launched in April 2012.
Pacira BioSciences, Inc. (Nasdaq: PCRX) has resolved all investigations by the U.S. Department of Justice and other agencies regarding its marketing of EXPAREL®. The settlement amounts to approximately $3.5 million, though Pacira denies any wrongdoing. This conclusion follows a five-year investigation into the company's sales practices. Pacira's chief administrative officer expressed satisfaction in closing this chapter while reaffirming their commitment to legal compliance and non-opioid pain management solutions.
Pacira BioSciences, Inc. (Nasdaq: PCRX) announced the pricing of $350 million in convertible senior notes due 2025, increased from an initial offering of $300 million. The net proceeds are estimated at $339 million, with $211.1 million designated to repurchase outstanding 2.375% notes due 2022. The notes bear a 0.750% interest rate and are convertible under specific conditions starting February 2025, with an initial conversion price of $71.78 per share, a 32.5% premium over the recent closing price. The offering settlement is expected on July 10, 2020.
FAQ
What is the current stock price of Pacira Biosciences (PCRX)?
What is the market cap of Pacira Biosciences (PCRX)?
What is the core focus of Pacira BioSciences Inc?
How does Pacira differentiate its products in the market?
What are the key commercial-stage products offered by Pacira?
What technology underpins Pacira's drug delivery system?
How does Pacira address the issue of opioid dependency?
What is PCRX-201 and what potential does it hold?
Which healthcare settings benefit from Pacira's therapies?
What role do reimbursement strategies play in Pacira's business model?
How does Pacira support clinical decision-making and patient care?
